Mentions
Extended reach
Total likes
Video views
All 9 dated mentions so far are from Aug 2025.
AI synopsis
The discussions display high interest with phrases like 'game-changing' and focus on the potential to enhance anti-tumor responses by targeting the STUB1-CHIC2 pathway. Many posts delve into mechanistic details, such as IL-27 receptor regulation, demonstrating moderate engagement and an understanding of the research's significance, which together highlight the perceived potential impact on cancer immunotherapy.
Most discussions reflect support for the findings, emphasizing the importance of the STUB1-CHIC2 complex in tumor immunity.
Participants show high curiosity, often referencing the potential therapeutic implications and broader relevance to cancer research.
Posts contain specific references to molecular mechanisms and experimental results, indicating moderate reflection and understanding.
The discussions suggest recognition of the study's potential to influence future immunotherapy strategies, though some mention the need for further research.
A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity ->Nature | More info from EcoSearch
A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity | Nature Immunology https://t.co/5tKfbnWfVe
CRISPR-based studies identify STUB1 as a negative regulator of CD8 T cell anti-tumor activity, with knockout improving tumor control by modulating cytokine receptor expression, highlighting potential immunotherapy…
CRISPR studies reveal that the E3 ubiquitin ligase STUB1 negatively impacts CD8 T cell anti-tumor activity by regulating cytokine receptor expression, especially IL-27 receptor α. Targeting the STUB1-CHIC2 pathway could…
CRISPR in vivo screens identified STUB1, an E3 ubiquitin ligase, as a key negative regulator of CD8 T cell anti-tumor activity. Knocking out Stub1 enhances tumor control by modulating cytokine receptor expression…
CRISPR screens reveal that knocking out STUB1 improves CD8 T cell anti-tumor activity by modulating cytokine receptors, offering a potential strategy to boost cancer immunotherapy.
In vivo CRISPR screens identify STUB1 as a negative regulator of CD8 T cell anti-tumor activity. Knocking out Stub1 improves tumor control by modulating cytokine receptor expression, highlighting potential for…
In vivo CRISPR screens identified STUB1's role in inhibiting CD8 T cell anti-tumor response; knocking out Stub1 enhances tumor control by modulating cytokine receptor expression.
In vivo CRISPR screens identified that the E3 ubiquitin ligase STUB1 negatively regulates anti-tumor CD8 T cell function. Knocking out Stub1 improves tumor control by modulating cytokine receptor expression, especially…
A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity | Nature Immunology https://t.co/5tKfbnWfVe
A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity ->Nature | More info from EcoSearch